Royal Medical Center review

What it is

Royal Medical Center is a physician-led nationwide telehealth practice centred on hormone therapy, founded by Dr. Dagoberto Rodriguez, MD — an Emory-trained physician, formerly chairman at Coral Springs Medical Center and a University of Miami faculty member, in practice since 1990. Its catalogue spans testosterone replacement for men, hormone and testosterone therapy for women, an injectable peptide line, ED treatments, hair products, vitamin injections and a compounded tirzepatide weight-loss program. The peptide shelf carries sermorelin acetate and a tesamorelin/ipamorelin combination sold as one- and two-month supplies, alongside BPC-157, PT-141, GHK-Cu and injectable Lipo-C.

How it works

A storefront-and-consultation model with all-inclusive program pricing: its own copy describes bundles covering medication, supplies, injections, lab monitoring and physician follow-ups, and the testosterone program is built as a protocol rather than a single drug. That protocol structure is the most clinically literate thing in this batch — testosterone plus a testicular stimulant listed as clomiphene, enclomiphene or gonadorelin, plus an estrogen blocker — because it addresses the two predictable consequences of exogenous testosterone, testicular suppression and aromatisation, instead of ignoring them. The verification problem is severe and we are not going to soften it. Every attempt to load royalmedicalcenters.com, from multiple clients and multiple user agents, returned a Cloudflare managed challenge; no page, sitemap or product listing would render. That means the catalogue and protocol structure described here come from the provider record and from indexed product pages rather than from a page we read live today, and it means no dollar figure of theirs appears in this review or on their card. Treat every number you see quoted for this practice elsewhere as unconfirmed until you can see it yourself. Disclosure beyond that is thin regardless: no LegitScript badge, no operating legal entity, no named pharmacy partner and no 503A or 503B designation, no state list behind the nationwide claim, and no refund, cancellation or insurance policy stated. Its record also flags a headline "starting at $116/mo" that conflicts with the practice's own program pricing — a discrepancy to raise on the phone before you commit.

Pricing transparency

We are not quoting a peptide or testosterone price for Royal Medical Center, because we could not load a single page of its storefront to verify one. What can be said about the structure: peptides are sold as one- and two-month supplies rather than open-ended subscriptions, which at least defines a term; the testosterone program is sold as all-inclusive, described as covering labs, physical exams, physician consultations and medication; and a cheaper testosterone-only tier exists alongside the full protocol, which will not include the stimulant and blocker. Its record does carry a verified compounded tirzepatide ladder priced by dose from $450 to $1,100 a month — fully itemised, which is more transparent than a floor, and entirely irrelevant to what a peptide or a testosterone protocol costs. The one pricing fact worth acting on is the discrepancy its record flags: a "starting at $116/mo" headline that does not match the practice's own program prices. Before paying anything, get the specific molecule, the supply period, the total price, what the all-inclusive bundle covers and how often labs are repeated, in writing.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. No pharmacy partner is named and no 503A or 503B designation is given, so a buyer cannot verify who prepares the medication or under which framework; compounded sterile preparations are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, this catalogue spans the full range from well-supported to essentially unstudied, and the price does not tell you which is which. Testosterone replacement has a large randomised base including a cardiovascular safety trial, and needs ongoing haematocrit, PSA and testosterone monitoring. Enclomiphene and clomiphene raise endogenous testosterone by blocking oestrogen feedback at the pituitary and preserve fertility, but are not FDA-approved for that use in men; gonadorelin is a GnRH analogue used to maintain testicular signalling on testosterone therapy, with a sound rationale and thin comparative outcome data. Sermorelin is a GHRH analogue with a real mechanism and thin long-term outcome data. Tesamorelin is the outlier in the growth-hormone family with genuine randomised evidence — it is FDA-approved for HIV-associated lipodystrophy, and use outside that indication is off-label. Ipamorelin is a ghrelin-receptor secretagogue with essentially no controlled human outcome trials. BPC-157 has a large animal literature and no controlled human outcome trials, and is not an approved drug in any jurisdiction. PT-141 is approved only for generalised hypoactive sexual desire disorder in premenopausal women; anything else is off-label. GHK-Cu has essentially no controlled human outcome data. Individual results vary.

Pros and watch-outs

The evidence behind what Royal Medical Center prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• Tesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence

  A real, approved GHRH analog — for HIV-associated lipodystrophy specifically. What the pivotal trials showed, and why the longevity use is an extrapolation.

• Ipamorelin & CJC-1295: the honest evidence on GH secretagogue peptides

  They reliably raise growth hormone — that part is real. The muscle, fat-loss and anti-aging claims are not supported by human outcome data. A straight read.

• BPC 157: what the evidence actually shows (and what it doesn't)

  The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.

• PT-141 (bremelanotide): the evidence on a research-popular peptide that is actually FDA-approved

  Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.

• TRT: what testosterone therapy is actually proven to do

  An FDA-approved therapy for diagnosed hypogonadism — with real but moderate benefits (sexual function, mood; not vitality), cardiovascular non-inferiority in TRAVERSE, and a real fertility trade-off.

• Enclomiphene: the evidence for restoring testosterone without replacing it

  Randomized trials, including two Phase III RCTs, show enclomiphene restores a man's own testosterone while preserving fertility — but it was never FDA-approved.

• Gonadorelin: real GnRH with a proven pump role — and an unproven TRT-adjunct pitch

  Gonadorelin is authentic synthetic GnRH with a legitimate diagnostic and pulsatile-pump fertility role — but the modern once-daily bolus use as an hCG substitute on TRT ignores the rhythm the evidence depends on.

How Royal Medical Center compares

A few alternatives worth a look, depending on what you’re optimizing for.

• RHRxION Health

  A flat NAD⁺ price from a platform that says on the page what the evidence does not support

  See RxION Health →
• RMRemi Meds

  NAD⁺ buyers who want the weekly volume stated, not just a monthly fee

  See Remi Meds →
• RHRixa Health

  Named clinicians and named pharmacies, if you will ask what the peptide is at consult

  See Rixa Health →